Jurkiewicz, M., Yeh, R., Shu, C. A., Hsiao, S. J., Mansukhani, M. M., Saqi, A., & Fernandes, H. (2025). Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers. Journal of Molecular Pathology, 6(1), 5. https://doi.org/10.3390/jmp6010005

Marks, L. J., Ritter, V., Agrusa, J., Kamdar, K. Y., Rivers, J., Gardner, R. A., Ehrhardt, M. J., Devine, K. J., Phillips, C. A., Reilly, A. F., August, K., Weinstein, J. L., Satwani, P., Forlenza, C. J., Smith, C. M., Greer, C., Afify, Z., Lin, C. H., Belsky, J. A., … Aftandilian, C. (2025). Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment and outcomes in the targeted drug era. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014745

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Mallick, S., Henick, B., Georgis, Y., Zhakula, N., Concepcion-Crisol, C., Herzberg, B., & Taylor, A. (2024). 1365 Chromosome 19p status associates with clinical outcomes in a histology-dependent manner in non-small cell lung cancer. Regular and Young Investigator Award Abstracts, A1529–A1529. https://doi.org/10.1136/jitc-2024-sitc2024.1365

Neugut, A. I., & Bates, S. E. (2024). Highlights of ASCO 2024. The Oncologist, 29(11), 913–917. https://doi.org/10.1093/oncolo/oyae250

Chen, L. N., Keating, C., Leb, J., Saqi, A., & Shu, C. A. (2024). Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer. Respiratory Medicine Case Reports, 51, 102091. https://doi.org/10.1016/j.rmcr.2024.102091

Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology, 19(33), 2213–2225. https://doi.org/10.2217/fon-2023-0284

Shuryak, I., Wang, E., & Brenner, D. J. (2024). Understanding the impact of radiotherapy fractionation on overall survival in a large head and neck squamous cell carcinoma dataset: a comprehensive approach combining mechanistic and machine learning models. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1422211

Mazul, A. L., Barrett, T. F., Colditz, G., Parikh, A. S., Ramadan, S., Zevallos, J. P., Rich, J. T., Harbison, R. A., Jackson, R. S., Pipkorn, P., Zolkind, P., Tirosh, I., & Puram, S. V. (2024). A hybrid epithelial/mesenchymal state in head and neck cancer: A biomarker for survival with differential prognosis by self-reported race. Med, 5(7), 826-831.e3. https://doi.org/10.1016/j.medj.2024.05.014

Madarang, E., Lykon, J., Zhao, W., Sekeres, M. A., Bradley, T., Chandhok, N. S., Taylor, J., Venugopal, S., Koru-Sengul, T., Iyer, S. G., Gilbert, J. S., Miller, R. M., Nanni, J., Zacheo, I., Mattei, A., Al Ali, N., Kishtagari, A., Marconi, G., Sallman, D. A., … Watts, J. (2024). Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia. Blood Neoplasia, 1(2), 100016. https://doi.org/10.1016/j.bneo.2024.100016

Chen, L. N., Stanifer, B. P., Sonett, J. R., & Shu, C. A. (2024). Advancing neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC): commentary on the Lung Cancer Mutation Consortium 3 trial (LCMC3). AME Clinical Trials Review, 2, 37–37. https://doi.org/10.21037/actr-24-13

Felip, E., Shu, C. A., Aguilar, A., Tang, K.-J., García Campelo, M. R., Lee, K.-Y., Delmonte, A., Sabari, J., Girard, N., Mansfield, A. S., Park, K., Zhou, C., Xia, K., Bhattacharya, A., Wade, M., Baig, M., Agrawal, T., Mahadevia, P., Knoblauch, R. E., & Sanborn, R. E. (2024). 2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON. ESMO Open, 9, 102581. https://doi.org/10.1016/j.esmoop.2024.102581

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Salvatore, M. M., Liu, Y., Peng, B., Hsu, H. Y., Saqi, A., Tsai, W.-Y., Leu, C.-S., & Jambawalikar, S. (2024). Comparison of lung cancer occurring in fibrotic versus non-fibrotic lung on chest CT. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-023-04645-y

Diaz, M., Chudsky, S., Pentsova, E., & Miller, A. M. (2024). Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors. Translational Oncology, 41, 101881. https://doi.org/10.1016/j.tranon.2024.101881

Oxnard, G. R., Chen, R., Pharr, J. C., Koeller, D. R., Bertram, A. A., Dahlberg, S. E., Rainville, I., Shane-Carson, K., Taylor, K. A., Sable-Hunt, A., Sholl, L. M., Teerlink, C. C., Thomas, A., Cannon-Albright, L. A., Fay, A. P., Ashton-Prolla, P., Yang, H., Salvatore, M. M., Addario, B. J., … Garber, J. E. (2023). Germline EGFR Mutations and Familial Lung Cancer. Journal of Clinical Oncology, 41(34), 5274–5284. https://doi.org/10.1200/jco.23.01372

Lee, J. M., Toloza, E. M., Pass, H. I., Johnson, B. E., Heymach, J. V., Sholl, L., Saqi, A., Travis, W. D., Wistuba, I., Lin, J., Kris, M. G., Spira, A. I., Shu, C. A., Saltos, A. N., Ding, B., Schulze, K., Zhu, Q., Ngiam, C., Bara, I., & Chaft, J. E. (2023). P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC. Journal of Thoracic Oncology, 18(11), S297–S298. https://doi.org/10.1016/j.jtho.2023.09.511

Leighl, N., Cho, B. C., Hiret, S., Han, J.-Y., Lee, K. H., Llacer Perez, C., Krebs, M. G., De Braud, F., Haura, E., Sanborn, R. E., Yang, J. C.-H., Shu, C. A., Goto, K., Nishio, M., Zhao, J., Wang, Z., Tomasini, P., Felip, E., Goldman, J. W., … Spira, A. I. (2023). OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. Journal of Thoracic Oncology, 18(11), S93–S94. https://doi.org/10.1016/j.jtho.2023.09.105

LaRose, M., Zhou, M., Lu, S., Wei, H., Bates, S. E., Schwartz, L., & Fojo, A. T. (2023). 1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib. Annals of Oncology, 34, S766–S767. https://doi.org/10.1016/j.annonc.2023.09.2361

Le, X., Patel, J., Shum, E., Sanborn, R. E., Baik, C. S., Shu, C. A., Kim, C., Fidler, M. D., Hall, R., Hanna, N., Mohindra, N., Sabari, J. K., Heeke, S., Hernandez, M., Gray, J. E., Heymach, J. V., & Saltos, A. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology, 34, S1313–S1314. https://doi.org/10.1016/j.annonc.2023.10.072

Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W. A., Borczuk, A., Chung, J.-H., Glass, C., Lopez, J. M., Roden, A. C., Sholl, L., Weissferdt, A., Posadas, J., Walker, A., Zhu, H., Wijeratne, M. T., Connolly, C., Wynes, M., Bota-Rabassedas, N., … Wistuba, I. (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017

Hijiya, N., Heneghan, M., Kapoor, S., Dhamal, V., Hoch, M., Descamps, L., Cardoso, A. P., & Pollard, J. (2023). POSTER: CML-532 ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00574-8

Thummalapalli, R., Bernstein, E., Herzberg, B., Li, B. T., Iqbal, A., Preeshagul, I., Santini, F. C., Eng, J., Ladanyi, M., Yang, S.-R., Shen, R., Lito, P., Riely, G. J., Sabari, J. K., & Arbour, K. C. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, 7. https://doi.org/10.1200/po.23.00030

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., Vokes, N. I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P. M., Anagnostou, V., Riess, J. W., … Gainor, J. F. (2023). Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 55(5), 807–819. https://doi.org/10.1038/s41588-023-01355-5

Herzberg, B. O., & Manji, G. A. (2023). KRAS: Druggable at Last. The Oncologist, 28(4), 283–286. https://doi.org/10.1093/oncolo/oyad014

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223

Savari, O., Febres‐Aldana, C., Chang, J. C., Fanaroff, R. E., Ventura, K., Bodd, F., Paik, P., Vundavalli, M., Saqi, A., Askin, F. B., Travis, W. D., & Rekhtman, N. (2022). Non‐small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours. Histopathology, 82(2), 242–253. Portico. https://doi.org/10.1111/his.14801

Van Egeren, D., Kohli, K., Warner, J. L., Bedard, P. L., Riely, G., Lepisto, E., Schrag, D., LeNoue-Newton, M., Catalano, P., Kehl, K. L., Michor, F., Fiandalo, M., Foti, M., Khotskaya, Y., Lee, J., Peters, N., Sweeney, S., Abraham, J., … Walther, Z. (2022). Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-21448-1

Olazagasti, C., Ehrlich, M., & Seetharamu, N. (2022). One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.995408

Pass, H., Kim, A. W., Felip, E., Shu, C. A., Ferris, A., Frueh, M., Gitlitz, B. J., Troutman, S., Petrek, H., Liu, X., Hsu, J., Patil, N., & Meng, R. D. (2022). 970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC. Annals of Oncology, 33, S990–S991. https://doi.org/10.1016/j.annonc.2022.07.1096

Ricciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N. I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V. R., Leonardi, G. C., Plodkowski, A. J., Gupta, H., Cherniack, A. D., … Awad, M. M. (2022). Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 8(8), 1160. https://doi.org/10.1001/jamaoncol.2022.1981

Park, K., Sabari, J., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology, 33, S482. https://doi.org/10.1016/j.annonc.2022.05.104

Biswas, A. K., Han, S., Tai, Y., Ma, W., Coker, C., Quinn, S. A., Shakri, A. R., Zhong, T. J., Scholze, H., Lagos, G. G., Mela, A., Manova-Todorova, K., de Stanchina, E., Ferrando, A. A., Mendelsohn, C., Canoll, P., Yu, H. A., Paik, P. K., Saqi, A., … Acharyya, S. (2022). Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse inEGFR-Mutant Lung Cancer. Cancer Discovery, 12(4), 1002–1021. https://doi.org/10.1158/2159-8290.cd-21-0910

Olazagasti, C., Ehrlich, M., Kohn, N., Aviles, K., Hoilett, A., & Seetharamu, N. (2022). Missed Opportunities? An Observational Analysis of Lung Cancer Screening Utilization Amongst Patients With Lung Cancer. Cancer Control, 29. https://doi.org/10.1177/10732748221077959